Misetionamide is an orally oxathiazin-like compound. Misetionamide is a glyceraldede-3-phosphate dedrogenase (GAPDH) inhibitor with antineoplastic activity. Misetionamide can be used for the research of cancer.
Misetionamide (OTD) (0-2000 μM; 0-72 h) induces cell death in TNBC cells[2].Misetionamide (OTD) (0-2000 μM; 12 h) inhibits TNBC cells proliferation[2].Misetionamide (OTD) (0-1000 μM; 18 h) induces necrosis and apoptosis in TNBC cells[2].Misetionamide (OTD) (250-1000 μM; 18 h) induces cell death by a ROS-dependent mechanism in TNBC cells[2].
References:
[1]. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information. 2022. 36(2):337. [2]. Jinih M, et al. Evaluation of the Cytotoxic Effects of the Novel Antineoplastic Agent 1,4,5-Oxathiazinane-4,4-dioxide on Triple Negative Breast Cancer Cells. Anticancer Res. 2021 May;41(5):2247-2256.